Yarrow Bioscience completes $172.5M offering and funds Q3 2026 results
Yarrow Bioscience Inc. reported Q3 2026 results, completed a $172.5M public offering extending cash runway to 2030, and announced Phase 2a topline results expected mid-2027.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed